Cargando…
Different Expression Levels of DLK2 Inhibit NOTCH Signaling and Inversely Modulate MDA-MB-231 Breast Cancer Tumor Growth In Vivo
NOTCH signaling is implicated in the development of breast cancer tumors. DLK2, a non-canonical inhibitor of NOTCH signaling, was previously shown to be involved in skin and breast cancer. In this work, we studied whether different levels of DLK2 expression influenced the breast cancer characteristi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836183/ https://www.ncbi.nlm.nih.gov/pubmed/35163478 http://dx.doi.org/10.3390/ijms23031554 |
_version_ | 1784649614766374912 |
---|---|
author | Naranjo, Ana-Isabel González-Gómez, María-Julia Baladrón, Victoriano Laborda, Jorge Nueda, María-Luisa |
author_facet | Naranjo, Ana-Isabel González-Gómez, María-Julia Baladrón, Victoriano Laborda, Jorge Nueda, María-Luisa |
author_sort | Naranjo, Ana-Isabel |
collection | PubMed |
description | NOTCH signaling is implicated in the development of breast cancer tumors. DLK2, a non-canonical inhibitor of NOTCH signaling, was previously shown to be involved in skin and breast cancer. In this work, we studied whether different levels of DLK2 expression influenced the breast cancer characteristics of MDA-MB-231 cells. We found that DLK2 overexpression inhibited NOTCH activation in a dose-dependent manner. Moreover, depending on the level of inhibition of NOTCH1 activation generated by different levels of DLK2 expression, cell proliferation, cell cycle dynamics, cell apoptosis, cell migration, and tumor growth in vivo were affected in opposite directions. Low levels of DLK2 expression produced a slight inhibition of NOTCH1 activation, and enhanced MDA-MB-231 cell invasion in vitro and cell proliferation both in vitro and in vivo. In contrast, MDA-MB-231 cells expressing elevated levels of DLK2 showed a strong inhibition of NOTCH1 activation, decreased cell proliferation, increased cell apoptosis, and were unable to generate tumors in vivo. In addition, DLK2 expression levels also affected some members of other cell signaling pathways implicated in cancer, such as ERK1/2 MAPK, AKT, and rpS6 kinases. Our data support an important role of DLK2 as a protein that can finely regulate NOTCH signaling and affect the tumor properties and growth dynamics of MDA-MB-231 breast cancer cells. |
format | Online Article Text |
id | pubmed-8836183 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88361832022-02-12 Different Expression Levels of DLK2 Inhibit NOTCH Signaling and Inversely Modulate MDA-MB-231 Breast Cancer Tumor Growth In Vivo Naranjo, Ana-Isabel González-Gómez, María-Julia Baladrón, Victoriano Laborda, Jorge Nueda, María-Luisa Int J Mol Sci Article NOTCH signaling is implicated in the development of breast cancer tumors. DLK2, a non-canonical inhibitor of NOTCH signaling, was previously shown to be involved in skin and breast cancer. In this work, we studied whether different levels of DLK2 expression influenced the breast cancer characteristics of MDA-MB-231 cells. We found that DLK2 overexpression inhibited NOTCH activation in a dose-dependent manner. Moreover, depending on the level of inhibition of NOTCH1 activation generated by different levels of DLK2 expression, cell proliferation, cell cycle dynamics, cell apoptosis, cell migration, and tumor growth in vivo were affected in opposite directions. Low levels of DLK2 expression produced a slight inhibition of NOTCH1 activation, and enhanced MDA-MB-231 cell invasion in vitro and cell proliferation both in vitro and in vivo. In contrast, MDA-MB-231 cells expressing elevated levels of DLK2 showed a strong inhibition of NOTCH1 activation, decreased cell proliferation, increased cell apoptosis, and were unable to generate tumors in vivo. In addition, DLK2 expression levels also affected some members of other cell signaling pathways implicated in cancer, such as ERK1/2 MAPK, AKT, and rpS6 kinases. Our data support an important role of DLK2 as a protein that can finely regulate NOTCH signaling and affect the tumor properties and growth dynamics of MDA-MB-231 breast cancer cells. MDPI 2022-01-29 /pmc/articles/PMC8836183/ /pubmed/35163478 http://dx.doi.org/10.3390/ijms23031554 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Naranjo, Ana-Isabel González-Gómez, María-Julia Baladrón, Victoriano Laborda, Jorge Nueda, María-Luisa Different Expression Levels of DLK2 Inhibit NOTCH Signaling and Inversely Modulate MDA-MB-231 Breast Cancer Tumor Growth In Vivo |
title | Different Expression Levels of DLK2 Inhibit NOTCH Signaling and Inversely Modulate MDA-MB-231 Breast Cancer Tumor Growth In Vivo |
title_full | Different Expression Levels of DLK2 Inhibit NOTCH Signaling and Inversely Modulate MDA-MB-231 Breast Cancer Tumor Growth In Vivo |
title_fullStr | Different Expression Levels of DLK2 Inhibit NOTCH Signaling and Inversely Modulate MDA-MB-231 Breast Cancer Tumor Growth In Vivo |
title_full_unstemmed | Different Expression Levels of DLK2 Inhibit NOTCH Signaling and Inversely Modulate MDA-MB-231 Breast Cancer Tumor Growth In Vivo |
title_short | Different Expression Levels of DLK2 Inhibit NOTCH Signaling and Inversely Modulate MDA-MB-231 Breast Cancer Tumor Growth In Vivo |
title_sort | different expression levels of dlk2 inhibit notch signaling and inversely modulate mda-mb-231 breast cancer tumor growth in vivo |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836183/ https://www.ncbi.nlm.nih.gov/pubmed/35163478 http://dx.doi.org/10.3390/ijms23031554 |
work_keys_str_mv | AT naranjoanaisabel differentexpressionlevelsofdlk2inhibitnotchsignalingandinverselymodulatemdamb231breastcancertumorgrowthinvivo AT gonzalezgomezmariajulia differentexpressionlevelsofdlk2inhibitnotchsignalingandinverselymodulatemdamb231breastcancertumorgrowthinvivo AT baladronvictoriano differentexpressionlevelsofdlk2inhibitnotchsignalingandinverselymodulatemdamb231breastcancertumorgrowthinvivo AT labordajorge differentexpressionlevelsofdlk2inhibitnotchsignalingandinverselymodulatemdamb231breastcancertumorgrowthinvivo AT nuedamarialuisa differentexpressionlevelsofdlk2inhibitnotchsignalingandinverselymodulatemdamb231breastcancertumorgrowthinvivo |